Journal of Cellular Signaling
ISSN: 2692-0638

Commentary - Journal of Cellular Signaling (2022) Volume 3, Issue 1

The Outcome of Tumor Ablation Therapies is Determined by Stress Signaling Networks

Mladen Korbelik*

Integrative Oncology Department, BC Cancer, Vancouver, BC, Canada

*Corresponding Author:
Prof. Dr. Mladen Korbelik
E-mail:mkorbelik@bccrc.ca

Received date: November 26, 2021; Accepted date: January 05, 2022

Citation: Korbelik M. The Outcome of Tumor Ablation Therapies is Determined by Stress Signaling Networks. J Cell Signal. 2022;3(1):1-4.

Copyright: © 2022 Korbelik M. This is an open-access article distributed under the terms of the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited.


Commentary

Increasingly prominent roles in interventional oncology are held by various tumor ablation therapies performed by direct applications of local acute trauma-inducing insult to the targeted lesion aiming for its rapid in situ destruction. These therapies include treatments based on various forms of thermal energy delivery (photothermal, cryoablation, microwave ablation, radiofrequency ablation), non-thermal illumination (photodynamic therapy), electric field exposure, or high hydrostatic pressure [1-3]. Common injury inflicted in cells of tumors treated by ablation therapies is the impairment of proteostasis due to accumulation of misfolded/damaged proteins. This is sensed by afflicted cells as a trauma typically associated with thermal or oxidative stress that threatens the integrity and homeostasis at the affected site [4]. These types of stress provoke evolutionary well conserved canonic protection mechanisms based on cellular stress signaling network that serves to re-balance biochemical activities within the cell. They work by conversing the incoming signal (appearance of stressor molecule) towards downstream effector molecules involved in transcriptome reprogramming aimed at activation or inhibition of targeted biochemical tasks [4,5]. The aim of this commentary is to emphasize that the activity of the engaged intracellular signaling pathways determines the fate of involved tumor cells and ultimately the outcome of the applied therapies.

Stress signaling network consist of interlinked intracellular signal transduction programs providing defense mechanisms for mitigating stress challenge expressed as adaptive responses developed to assure restored homeostasis and survival of afflicted cells. This is attained either by improving the resistance to stress or by reducing the stress impact with increased tolerance [6]. The former is attained by enhancing the clearance of induced primary stressor molecules, while the latter is mediated through limiting the stress damage (e.g. by improved protein folding capacity) [7]. While the initial response to stress trauma is engaged to help the cells to defend against the insult and recover from it, in case when the damaging stimulus remains unresolved the cellular signaling cascades are switched towards self-destructive programs leading to cell death or elimination through immune rejection [4,8].

Signal transduction cascades incorporated in the stress signaling network can be grouped in four programs [8]:

i) Rectifying changes in gene and protein activity aimed at suspending global protein synthesis while expanding the expression of protein chaperons, folding enzymes and other stress-relieving proteins. The best known among these cell autonomous pathways are heat shock response (HSR), unfolded protein response (UPR), integrated stress response (ISR), and antioxidant response [9-11];

ii) Repairing damaged cellular membranes in order to maintain cell integrity, primarily through the engagement of sterol regulatory element-binding proteins (SREBs) pathway that mediates the metabolism of cholesterol and fatty acid metabolism control together with the associated caspase-1 activity [12];

iii) Amplifying removal of irreparably damaged proteins and cells with programs including the ER-associated protein degradation response (ERAD), autophagy, as well as apoptosis and other cell death signaling cascades [4,13];

iv) Generation of immunogenic cell death and ensuing immune elimination cascades [8].

In adaptive stress response pathways, key pro-survival roles are held by UPR/ISR sensor kinases PERK and IRE1, transcription factor HSF1 of HSR, and by oxidative proteinfolding controlling enzyme protein disulfide isomerase (PDI) that actively participates in the UPR and antioxidant response [4,8]. Selective specific inhibitors of these signaling elements drastically reduce survival of tumor cells treated by ablation therapies and could be useful clinically to improve the outcome of tumor treatment with these therapies [8].

The adaptive stress responses are additionally fine-tuned by cross-talk with c-Jun amino-terminal kinase (JNK) and p38 mitogen-activated protein kinase (MAPK) signaling nodes controlling basic cellular metabolism [6]. The MAPK activity in turn regulates the expression of important master nuclear transcription factors, such as STAT3 and HIF-1, enabling them to play important roles in stress response [14,15]. The activity of HIF-1 markedly influences tumor growth because of the effects on angiogenesis, glucose metabolism, and cell survival [16]. By similarly modifying tumor microenvironment, STAT3 promotes angiogenesis, cell survival and immunosuppression [17]. The effects of specific inhibitors of STAT3 and HIF-1 on tumor cells treated by PDT (as a representative of ablation therapies) were examined in our studies. Tested were benzoic acid derivative NSC 74859 that selectively inhibits activation, dimerization and DNA-binding activity of STAT3, while aryloxyacetylaminobenzoic derivative LW6 was used as it promotes degradation of HIF-1α [18,19]. At the doses showing no detectable toxicity when used alone, both inhibitors significantly reduced the survival of tumor cells treated by PDT [20]. This finding reveals the pro-survival role of STAT3 and HIF- 1 in cells coping with PDT-mediated stress. Their inhibitors are good candidates for use as adjuvants for improving the clinical outcome of PDT and other ablation therapies. Importantly, even stronger reduction of survival was seen with cells treated by PDT and exposed to ceramidase inhibitor LCL521 [20]. This is consistent with the important role of sphingolipid activity in cellular stress signaling [21,22]. Indeed, PDT and other stress-inducing treatments were shown to have a pronounced impact on the sphingolipid profile in treated tumors due to their effects on the genes controlling metabolism of these lipids [23,24].

A crucial advantage that can be realized by the use of tumor ablation therapies is the re-establishment of immune control by breaking tumor immunotolerance [2,8]. Stress response signaling triggered by acute trauma in treated tumor site induced by localized thermal, oxidative or other stress caused by ablation therapies includes potent immune signal transduction activities (Figure 1). In addition to the avid non-infectious inflammatory signaling highlighted by the engagement of its key regulators such as nuclear transcription factor NFκB and expression of Toll-like receptors, this is dominated by the danger signaling cascade leading to the release of alarmins and the expression of damage-associated molecular patterns (DAMPs) [4,25]. These molecules from the cells whose appearance on the cell surface or release outside the cell turns them into signals for the mobilization of immune system are critical for the induction of immunogenic cell death [26,27]. The other component important for immune signaling is the abundant availability of tumor antigens derived from programmed cell death pathways with ensuing disposal and processing of dead cell material by phagocytes capable of antigen presentation activity [28,29]. Another decisive element is the stress-induced expression of highly immunogenic cryptic tumor antigens normally hidden within untranslated regions of tumor cell RNA [4,30].

For highly advantageous clinical outcome it is critical that the antitumor immune response orchestrated by tumor ablation therapies remains robust and long-lasting. This can be achieved by optimal choice of adjuvant immune stimulating agents. One such agent is IP-001, a specific variant of the carbohydrate biopolymer N-dihydrogalactochitosan, which is currently evaluated in clinical trials in combination with laserbased thermal ablation of advanced solid tumors [31].


Conflict of Interest

The author declared no conflict of interest.


References